Vivek Kumar Pandey

Dr. Vivek Kumar Pandey

Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Life Sciences
Verified
Journal Article
Closed access
VPVivek Kumar Pandey
Vivek Kumar Pandey
AMAlpana Mathur
Alpana Mathur
PKPoonam Kakkar
Poonam Kakkar

1 January 2016 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
SSShatrunajay Shukla
Shatrunajay Shukla
ASAnkita Sharma
Ankita Sharma
VPVivek Kumar Pandey
Vivek Kumar Pandey
SRS Raisuddin
S Raisuddin
PKPoonam Kakkar
Poonam Kakkar

1 July 2019 in Cellular Signalling
Verified
Journal Article
Closed access
VPVivek Kumar Pandey
Vivek Kumar Pandey
AMAlpana Mathur
Alpana Mathur
MKMohammad Fareed Khan
Mohammad Fareed Khan
PKPoonam Kakkar
Poonam Kakkar

1 May 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
AMAlpana Mathur
Alpana Mathur
VPVivek Kumar Pandey
Vivek Kumar Pandey
PKPoonam Kakkar
Poonam Kakkar

1 June 2017 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
AMAlpana Mathur
Alpana Mathur
VPVivek Kumar Pandey
Vivek Kumar Pandey
PKPoonam Kakkar
Poonam Kakkar
Progressive research in the past decade converges to the impact of PHLPP in regulating the cellular metabolism through PI3K/AKT inhibition. Aberrations in PKB/AKT signaling coordinates with impaired insulin secretion and insulin resistance, identified during T2D, obesity and cardiovascular disorders which brings in the relevance of PHLPPs in the metabolic paradigm. In this review, we discuss the impact of PHLPP isoforms in insulin signaling and its associated cellular events including mitochondrial dysfunction, DNA damage, autophagy and cell death. The article highlights the plausible molecular targets that share the role during insulin-resistant states, whose understanding can be extended into treatment responses to facilitate targeted drug discovery for T2D and allied metabolic syndromes.

6 October 2021 in Journal of Cell Communication and Signaling
Verified
Journal Article
Closed access
PDF file
MKMohammad Fareed Khan
Mohammad Fareed Khan
AMAlpana Mathur
Alpana Mathur
VPVivek Kumar Pandey
Vivek Kumar Pandey
PKPoonam Kakkar
Poonam Kakkar